Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Corre

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolutionRomain Corre, Isabelle Monnet, Lionel Moreau, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
British Journal of Cancer|February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trialElodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer|July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS CohortSolenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Clinical Lung Cancer|March 23, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
JAMA|March 8, 2012
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac outputSophie Dupuis-Girod, Isabelle Ginon, Jean-Christophe Saurin, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolutionRomain Corre, Isabelle Monnet, Lionel Moreau, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
British Journal of Cancer|February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trialElodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer|July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS CohortSolenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Clinical Lung Cancer|March 23, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
JAMA|March 8, 2012
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac outputSophie Dupuis-Girod, Isabelle Ginon, Jean-Christophe Saurin, et al.
Pageof 6